News | August 27, 2021
SEC recommends Phase I clinical trials for Reliance’s Covid-19 vaccine candidate
The company has to approach the DCGI for approval to commence the trials
The company has to approach the DCGI for approval to commence the trials
In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020
New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson Covid-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.
The boy becomes India’s youngest recipient to undergo bilateral lung transplantation.
In the last two years, Sai Life Sciences has made significant investments and progress in advancing its sustainability agenda as part of its organizational transformation initiative
Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
The aim is to give a fillip to R&D in the health sector to face the Covid-19 challenge
It is the first branded generic alternative to Fostair 100/6 pMDI
The foundation has been working closely with the Kidwai Memorial Institute of Oncology on several projects since 2001
Viraleze was developed for application in the nasal cavity to help reduce exposure to respiratory viruses, including SARS-CoV-2. The product is registered for sale in Europe and India, and available online in certain markets
Subscribe To Our Newsletter & Stay Updated
